الصفحة الرئيسية>>Signaling Pathways>> Proteases>> ACE>>Temocapril HCl

Temocapril HCl (Synonyms: CS 622)

رقم الكتالوجGC17034

Temocapril HCl هو مثبط للإنزيم المحول للأنجيوتنسين (ACE) عن طريق الفم.

Products are for research use only. Not for human use. We do not sell to patients.

Temocapril HCl التركيب الكيميائي

Cas No.: 110221-44-8

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
31٫00
متوفر
5mg
27٫00
متوفر
10mg
43٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Temocapril Hydrochloride is a long-acting angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension. Target: ACETemocapril hydrochloride is a novel prodrug-type angiotensin-I converting enzyme (ACE) inhibitor, lowering of the dose of temocapril might be recommended only in patients with severe renal insufficiency [1]. Temocapril is regarded as an ACE inhibitor the disposition and efficacy of which are little affected in patients with impaired liver function [2].

References:
[1]. Nakashima, M., et al., Pharmacokinetics of temocapril hydrochloride, a novel angiotensin converting enzyme inhibitor, in renal insufficiency. Eur J Clin Pharmacol, 1992. 43(6): p. 657-9.
[2]. Furuta, S., et al., Pharmacokinetics of temocapril, an ACE inhibitor with preferential biliary excretion, in patients with impaired liver function. Eur J Clin Pharmacol, 1993. 44(4): p. 383-5.

مراجعات

Review for Temocapril HCl

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Temocapril HCl

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.